human fstl1  (R&D Systems)

Journal: bioRxiv

Article Title: Tumor-microvessel on-a-chip reveals sequential intravasation cascade of cancer cell clusters

doi: 10.1101/2024.02.28.582606

Figure Lengend Snippet: ( A ) Schematic illustration of the concept of in vitro semi-3D experiment treated with follistatin. Follistatin neutralizes activin secreted by HUVEC or AKTP organoids. ( B ) Schematic illustration of the in vitro semi-3D experiment. 0.1% BSA in PBS as a vehicle was added to the control. Image acquisition and expression analysis were performed at the indicated time points. ( C ) Representative time-dependent phase-contrast images of AKTP organoids with the HUVEC layer treated with follistatin or its vehicle alone. Invadopodia are indicated by the arrowheads. ( D ) Quantification of invadopodium formation on AKTP organoids under coculture with HUVEC treated without (control) or with follistatin. ( n = 3 for biological chip replicates) ( E ) Representative phase-contrast images (top) and CLSM images (bottom) of the immunostained HUVEC layer with AKTP organoids at day 6 after treated without (control) or with follistatin. ( F ) Relative mRNA levels of mesenchymal markers in HUVECs with AKTP organoids at day 6 after treated without (control) or with follistatin. ( n = 3 for biological chip replicates) ( G ) Relative mRNA levels of TGF-β family ligands in HUVEC at day 6 after treated without (control) or with follistatin. Inhibin βA indicates subunits of activin. ( n = 3 for biological chip replicates) The data in D, F and G are presented as the mean ± s.d.. Significant differences between control and treated condition were analyzed by two-way ANOVA in D or two-tailed unpaired Student’s t -test in F and G, respectively. p values are provided. ns not significant.

Article Snippet: For activin inhibition, we introduced 200 ng/mL follistatin (4889-FN-025, R&D Systems), an endogenous antagonist for activin , or 0.1% BSA in PBS as a vehicle.

Techniques: In Vitro, Control, Expressing, Two Tailed Test